List view / Grid view
18 April 2016 | By Victoria White, Digital Content Producer
A Opdivo and Yervoy combination regimen demonstrated a two-year OS rate of 69% compared to 53% for Yervoy alone in BRAF wild-type advanced melanoma...
18 April 2016 | By Victoria White, Digital Content Producer
With eight weeks of treatment, 97-98 percent of GT1-3 HCV infected patients without cirrhosis treated with ABT-493 and ABT-530 achieved sustained SVR12...
18 April 2016 | By Victoria White, Digital Content Producer
NICE has recommended Translarna (ataluren) for treating children aged 5 and over with Duchenne muscular dystrophy caused by a nonsense mutation...
15 April 2016 | By Victoria White, Digital Content Producer
Studies 108 and 110 were 48-week clinical trials evaluating TAF among 1,298 treatment-naïve and treatment-experienced patients with chronic HBV infection...
15 April 2016 | By Victoria White, Digital Content Producer
AstraZeneca has reported new Phase I extended follow-up data on osimertinib in both first- and second-line treatment of patients with non-small cell lung cancer (NSCLC).
15 April 2016 | By Victoria White, Digital Content Producer
The global viral infections market will grow from $74 billion in 2014 to $117.6 billion by 2021, according to business intelligence provider GBI Research...
15 April 2016 | By Victoria White, Digital Content Producer
AbbVie has announced new real-world data for Viekirax and Exviera, showing 96% of GT1 HCV patients and 100% of GT4 patients achieved SVR12...
15 April 2016 | By Victoria White, Digital Content Producer
The FDA has accepted a sBLA for Opdivo that seeks to expand the use of the therapy to patients with Hodgkin Lymphoma after prior therapies...
14 April 2016 | By Victoria White, Digital Content Producer
Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90% disease control and 59% response rate in malignant pleural mesothelioma...
14 April 2016 | By Victoria White, Digital Content Producer
AbbVie announced high SVR sates with Viekirax + Exviera regardless of the presence of resistance-associated variants prior to treatment in GT1 chronic HCV patients...
14 April 2016 | By Victoria White, Digital Content Producer
The EC has granted approval for the use of Opdivo (nivolumab) to treat patients with the most common forms of advanced lung and advanced kidney cancer...
14 April 2016 | By Victoria White, Digital Content Producer
Elbasvir/grazoprevir demonstrated superiority on efficacy and improvement on safety endpoints compared to sofosbuvir plus pegIFN/RBV...
14 April 2016 | By Victoria White, Digital Content Producer
The Cell and Gene Therapy Catapult has announced a positive interim review of a Phase I/II trial using WT1-TCR t-cell therapy to target acute myeloid leukaemia...
The psoriasis therapeutics market is set to more than double from $6.6 billion in 2014 to over $13.3 billion by 2024, according to research and consulting firm, GlobalData.
13 April 2016 | By Victoria White, Digital Content Producer
The sBLA is for patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy...
